 |
PDBsum entry 2p16
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Discovery of 1-(4-Methoxyphenyl)-7-Oxo-6-(4-(2-Oxopiperidin-1-Yl)phenyl)-4,5,6,7-Tetrahydro-1h-Pyrazolo[3,4-C]pyridine-3-Carboxamide (apixaban, Bms-562247), A highly potent, Selective, Efficacious, And orally bioavailable inhibitor of blood coagulation factor xa.
|
 |
|
Authors
|
 |
D.J.Pinto,
M.J.Orwat,
S.Koch,
K.A.Rossi,
R.S.Alexander,
A.Smallwood,
P.C.Wong,
A.R.Rendina,
J.M.Luettgen,
R.M.Knabb,
K.He,
B.Xin,
R.R.Wexler,
P.Y.Lam.
|
 |
|
Ref.
|
 |
J Med Chem, 2007,
50,
5339-5356.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Efforts to identify a suitable follow-on compound to razaxaban (compound 4)
focused on modification of the carboxamido linker to eliminate potential in vivo
hydrolysis to a primary aniline. Cyclization of the carboxamido linker to the
novel bicyclic tetrahydropyrazolopyridinone scaffold retained the potent fXa
binding activity. Exceptional potency of the series prompted an investigation of
the neutral P1 moieties that resulted in the identification of the
p-methoxyphenyl P1, which retained factor Xa binding affinity and good oral
bioavailability. Further optimization of the C-3 pyrazole position and
replacement of the terminal P4 ring with a neutral heterocycle culminated in the
discovery of
1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
(apixaban, compound 40). Compound 40 exhibits a high degree of fXa potency,
selectivity, and efficacy and has an improved pharmacokinetic profile relative
to 4.
|
 |
|
|
|
|
 |